FIGURE 5 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects Article Swipe

View

Related Concepts

Chronic lymphocytic leukemia Leukemia Cancer research Dimer Medicine Chemistry Immunology Organic chemistry

Alexandria P. Eiken , Audrey L. Smith , Sydney A. Skupa , Elizabeth Schmitz , Sandeep Rana , Sarbjit Singh , Siddhartha Kumar , Jayapal Reddy Mallareddy , Aguirre A. de Cubas , Akshay Krishna , Achyuth Kalluchi , M. Jordan Rowley , Christopher R. D’Angelo , Matthew A. Lunning , R. Gregory Bociek , Julie M. Vose , Amarnath Natarajan , Dalia El‐Gamal ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.1158/2767-9764.25880285.v1 · OA: W4398204194

SpiD3 synergizes with ibrutinib and elicits cytotoxic effects in ibrutinib-resistant CLL cells. A–D, Combination assays to test synergy between SpiD3 and ibrutinib (IBR; BTK inhibitor) in preclinical CLL models. HG-3 cells (A–B; n = 3 independent experiments) or CpG ODN 2006 (CpG; 3.2 µmol/L)-stimulated patient-derived CLL cells (C–D; n = 6) were treated with SpiD3, IBR, or both (1:1 ratio) for 72 hours. MTS assay was performed to detect the dose effect. A and C, Dose-effect of the single drugs and their combination (1:1 ratio). B and D, CI of the combined doses (0.5 µmol/L SpiD3 + 0.5 µmol/L IBR = 1 µmol/L on graph). CI values were calculated using the Chou-Talalay method by the software Compusyn. CI values >1 are antagonistic, CI values = 1 are additive, and CI values <1 are synergistic. E, Mitochondrial activity in parental wild-type (WT) and ibrutinib-resistant (IR) HG-3 cell lines were assessed by MTS assay following treatment with increasing concentrations of SpiD3 or IBR (72 hours; n = 6 independent experiments/cell line). IC50 values (mean ± SEM) are noted for each cell line. F and G, Representative immunoblot analyses of p-BTK (Tyr223), total BTK, p-PRAS (Thr246), total PRAS, p-ERK1/2 (Thr202/Tyr204), total ERK1/2, MYC, PARP (total and cleaved), IKKα, IKKβ, p65, and RELB in WT- and IR-HG3 cells treated with SpiD3 (1–2 µmol/L) or IBR (1 µmol/L) for 4 hours. BCR activation was induced by adding soluble α-IgM (10 µg/mL) for the last 15 minutes of treatment (n = 5 independent experiments). GAPDH served as the loading control. H, Spleen-derived malignant B cells from terminally diseased Eµ-Myc/TCL1 mice (n = 8) were stimulated ex vivo with 1X PMA/Ionomycin and treated with SpiD3 (0.25–2 µmol/L), IBR (1 µmol/L), or JQ-1 (1 µmol/L) for 48 hours. Proliferation was assessed via MTS assay and normalized to the unstimulated vehicle (dashed line). Asterisks indicate significance versus stimulated vehicle. *, P < 0.05; **, P < 0.01; ***, P < 0.001.